Promises
2 promises
Promise Tracker
0 delivered, 0 close, 2 missed.
View Promises →
Fortis Healthcare Limited — Q4 FY24
Fortis Healthcare reported a strong Q4 FY24 with consolidated revenue of ₹1,786 crore (+8.7% YoY) and EBITDA margin of 21.3% (+480bps YoY), driven by hospital business margin expansion to 22.4% (adjusted ~21%).
bullish
high
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Fortis Healthcare reported a strong Q4 FY24 with consolidated revenue of ₹1,786 crore (+8.7% YoY) and EBITDA margin of 21.3% (+480bps YoY), driven by hospital business margin expansion to 22.4% (adjusted ~21%). PAT grew 46.9% to ₹203 crore. Hospital revenue grew 10.3% YoY, supported by ARPOB growth of 10.8% (3% price, rest mix) and higher surgical volumes. Diagnostics revenue was soft (+2%) due to rebranding and one-offs, but non-COVID revenue grew 5%. Management guided for ~200bps YoY EBITDA margin improvement in FY25, with brownfield bed additions of ~700 beds (including Manesar) and a target of 6,000 beds over next few years. Key risks include potential dilution from Agilus put option exercise (~₹1,200-1,300 crore) and ongoing legal cases (₹30-50 crore annual cost).
फोर्टिस हेल्थकेयर ने चौथी तिमाही में अच्छा प्रदर्शन किया। कंपनी की कुल कमाई ₹1,786 करोड़ रही, जो पिछले साल से 8.7% ज्यादा है। कंपनी की कमाई और खर्च के बीच का अंतर (EBITDA मार्जिन) 21.3% रहा, जो पिछले साल से 4.8% बेहतर है। अस्पतालों से कमाई 10.3% बढ़ी, क्योंकि मरीजों पर ज्यादा खर्च हुआ और सर्जरी बढ़ीं। मुनाफा (PAT) 46.9% बढ़कर ₹203 करोड़ हो गया। डायग्नोस्टिक्स से कमाई सिर्फ 2% बढ़ी, लेकिन कोविड के बिना यह 5% बढ़ी। कंपनी अगले साल मार्जिन में 2% और सुधार चाहती है। वह अगले कुछ सालों में 6,000 बिस्तर जोड़ने की योजना बना रही है। मुख्य जोखिमों में आगिलस के शेयर खरीदने का दबाव (₹1,200-1,300 करोड़) और कानूनी मामलों का सालाना खर्च (₹30-50 करोड़) शामिल है।
Promises0 met · 2 missedRisks4 trackedTranscriptfull text
Research workspace
Focused Modules
Risks
4 risks
Risk Intelligence
Agilus put option liability could strain balance sheet
View Risks →
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
Hospital ARPOB
₹2.22 crore
+10.8% YoY
Driven by case mix improvement and 3% price increase; management expects 5-6% growth going forward.
Hospital Occupancy
65%
-2pp YoY
Occupancy declined due to new bed additions and underperformance in 3 hospitals; currently running at ~70%.
Agilus Non-COVID Revenue Growth
5%
+5% YoY
Non-COVID revenue grew 5% in Q4 and 6% for FY24; volumes grew 0.6% in Q4.
Key Specialties Revenue Share
62%
+1pp YoY
Oncology, cardiac, neuro, renal grew 13% YoY, driving ARPOB and margin improvement.
What Changed vs Last Quarter
NEW
FY25 EBITDA margin improvement of ~200bps YoY
Hospital operating EBITDA margin expected to improve by ~200bps in FY25, building on FY24's 18.6% (hospital) and 18.4% consolidated.
NEW
Brownfield bed addition of ~700 beds in FY25
Includes 50 beds each at Faridabad and Kalyan, 100 beds at Manesar (Q2), 100 beds at Kolkata (Q1), and beds at BG Road (Q2).
NEW
Medium-term ARPOB growth of 4-5%
ARPOB growth expected to moderate to 4-5% in medium term from 10.8% in FY24, driven by 2-2.5% price increases and case mix improvement.
NEW
Agilus put option resolution by Q2 FY25
Management expects to finalize the put option (due Oct 2024) by August-September 2024, with options including IPO revival or buyout via debt/equity.
DROPPED
Hospital EBITDA margin target of 20% by end of FY24
Management expects to achieve 20% EBITDA margin for the hospital business by year-end, driven by occupancy improvement and cost optimization.
DROPPED
Long-term hospital EBITDA margin target of 25% in 3-4 years
Over the next 3-4 years, as brownfield bed expansions ramp up, management aims for 25% EBITDA margin.
DROPPED
~2,200 brownfield beds over next 4 years
Brownfield bed expansion plan to add ~2,200 beds, with ~710 beds expected in FY25, including the Manesar acquisition.
DROPPED
Occupancy expected to trend toward 70% in coming quarters
Management expects occupancy to recover to ~70% in Q4 FY24 and next year, driven by seasonal recovery and international patient rebound.
NEW RISK
Agilus put option liability could strain balance sheet
If PE investor exercises put option, Fortis may need to raise ~₹1,200-1,300 crore, potentially via debt or equity, impacting leverage or dilution.
NEW RISK
Ongoing legal cases and brand litigation costs
Annual legal costs of ₹30-50 crore related to legacy issues (brand, forensic audit) may persist until resolution; Supreme Court stay on promoter shareholding dismissed.
NEW RISK
Diagnostics business recovery slower than expected
Agilus volumes grew only 0.6% in Q4 despite rebranding; competitive pressures and government business provisions may delay margin recovery.
NEW RISK
CGHS rate revision uncertainty
Government revenue (20% of hospital) may benefit from CGHS rate revision, but timing and quantum are uncertain; not factored into guidance.
RISK GONE
Occupancy ramp-up may be slower than expected
New bed additions could dilute occupancy, delaying margin expansion. Management acknowledged this but expects gradual ramp-up.
RISK GONE
International patient revenue vulnerable to geopolitical shocks
Flat international revenue in Q3 due to Middle East tensions; recovery seen but risks remain from geopolitical instability.
RISK GONE
Low-margin hospitals may take longer to turn around
~950 beds in hospitals with <10% EBITDA margin; structural improvements like adding specialties will take 2-3 years.
RISK GONE
Clinician attrition at key hospitals
FMRI Gurgaon saw a premium cardiac clinician depart, impacting Q3 performance. New clinician expected to join in Q4.
🤫 Topics management stopped discussing
Mentioned in Q1 FY24, Q2 FY24, Q3 FY24
Brownfield bed expansion plan to add ~2,200 beds, with ~710 beds expected in FY25, including the Manesar acquisition.
Mentioned in Q1 FY24, Q2 FY24, Q3 FY24
Management expects to achieve 20% EBITDA margin for the hospital business by year-end, driven by occupancy improvement and cost optimization.
Mentioned in Q1 FY24, Q2 FY24
Management identified potential delays in brownfield bed commissioning as a key risk to achieving FY25 margin targets.
Mentioned in Q1 FY24, Q2 FY24
Rapid growth in medical oncology (lower margin) relative to surgical oncology could cap margin expansion despite absolute EBITDA growth.
Fast read
Guidance and risk preview
Hospital operating EBITDA margin expected to improve by ~200bps in FY25, building on FY24's 18.6% (hospital) and 18.4% consolidated.
If PE investor exercises put option, Fortis may need to raise ~₹1,200-1,300 crore, potentially via debt or equity, impacting leverage or dilution.
View Risks →